EP0698039A1 - Peptides de suppression de la proliferation de cellules souches myeloides et de traitement du choc septique - Google Patents

Peptides de suppression de la proliferation de cellules souches myeloides et de traitement du choc septique

Info

Publication number
EP0698039A1
EP0698039A1 EP94916812A EP94916812A EP0698039A1 EP 0698039 A1 EP0698039 A1 EP 0698039A1 EP 94916812 A EP94916812 A EP 94916812A EP 94916812 A EP94916812 A EP 94916812A EP 0698039 A1 EP0698039 A1 EP 0698039A1
Authority
EP
European Patent Office
Prior art keywords
lys
ala
pro
arg
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94916812A
Other languages
German (de)
English (en)
Inventor
Hal E. Broxmeyer
Scott Cooper
Li Lu
Robert N. Moore
Robert Kreisberg
Melinda Detrick Kreisberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Publication of EP0698039A1 publication Critical patent/EP0698039A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the proliferation and differentiation of hematopoietic progenitor cells are regulated by an interactive network of stimulatory and inhibitory molecules.
  • the bio olecules have the capacity to directly stimulate the proliferation and/or differentiation of progenitor cells, or to act indirectly by enhancing or suppressing the production or action of other cytokines.
  • Many of the cytokines are multifunctional, and may manifest stimulatory or suppressive activity depending upon the target cell or assay system.
  • EPO Erythrop ⁇ ietin
  • G-CSF granulocyte-colony stimulating factor
  • GM-CSF granulocyte macrophage- colony stimulating factor
  • H ferritin suppress growth factor induced clonal proliferation of myeloid progenitors in vitro, and H ferritin has suppressive activity when administered to mice. Both immature and more mature progenitor cells are responsive to inhibition by H ferritin.
  • Macrophage inflammatory protein (M ⁇ P)-l ⁇ has suppressive activity on more immature progenitor cells, including human and murine colonies forming units of granulocytes, erythrocytes, macrophages, and megakaryocytes (CFU-GEMM) and murine CFU-A.
  • interferons IFNs
  • TNFs tumor necrosis factors
  • PGEi and PGE 2 prostaglandins
  • inhibin transforming growth factor- ⁇
  • TGF- ⁇ transforming growth factor- ⁇
  • the iron-binding protein lactoferrin exerts indirect suppressive activity by decreasing the production or release of colony stimulating factors or IL-1 from onocytes and macrophages.
  • the suppressor molecule has an apparent molecular weight of 8 kD, which is similar to MlP-l ⁇ , but it is apparently biochemically and immunologically distinct from MlP-l ⁇ .
  • U.S. Patent No. 4,384,991 describes an inhibitor purified from granulocytes which inhibits the proliferation of normal and leukemic myeloid cells.
  • the inhibitor is reported to have the amino acid composition 94/28013
  • Cytokines which have stimulatory effects on myelopoiesis have clinical utility in the treatment of chemotherapy-induced myelosuppression.
  • Negative regulators are potentially useful in treatment of hematopoietic disorders by dampening blood cell production in hyperproliferative states and for selectively placing normal progenitors out of cycle and thus in a reversibly protected state from the effects of S-phase specific chemotherapeutic drugs. Accordingly, there is a need in the art for clinically useful suppressors of myelogenesis.
  • Gram-negative sepsis is a progressive, injurious systemic inflammatory response to infection in which bacterial endotoxin triggers biochemical events that lead to serious complications such as shock, adult respiratory distress syndrome, and disseminated intravascular coagulation.
  • therapies for sepsis and septic shock mortality remains unacceptably high. Accordingly, there remains a need in the field for effective therapies for the treatment and prevention of sepsis and septic shock.
  • the peptides of the present invention are useful in the treatment of myeloid proliferative disorders, such as leukemia, and for protecting hematopoietic cells prior to chemotherapy by suppressing myelopoiesis.
  • the peptides of the present invention are also useful in the treatment and prevention of septic shock.
  • the present invention is directed, in one embodiment, to biologically active peptides comprising at least five amino acids and further comprising the sequence Ala-Lys-Pro-Arg.
  • the peptide comprises the sequence Lys-Ala-Lys-Pro-Arg.
  • the peptide comprises the sequence Ala-Lys-Pro-Arg-Ala.
  • the biologically active peptide is Glu-Thr- Val-Ile-Met-Lys-Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro.
  • the peptide is Glu-Thr-Val- Ile-Met-Lys-Ala-Lys-Pro-Arg.
  • the peptide is Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro.
  • the present invention also encompasses pharmaceutical compositions containing a peptide comprising the sequence Ala-Lys-Pro-Arg, and the use of the peptides comprising the sequence Ala-Lys-Pro-Arg in suppressing the proliferation of myeloid progenitor cells and in the prevention and treatment of septic shock.
  • the present invention provides a method of treatment of myelopoietic hyperproliferative disorders.
  • the present invention further provides a method of reducing chemotherapy-induced myelosuppression.
  • Yet another aspect of the present invention provides a method of prevention of endotoxin-induced septic shock. 94/28013
  • Figure 1 is a graph providing the results of a competitive ELISA comparing capacities of soluble ferritin and 14-mer peptide to interfere with binding of anti-peptide IgG with affixed peptide antigen.
  • the present invention is directed to biologically active peptides which suppress the proliferation of myeloid progenitor cells.
  • the peptides of the present invention contain from five to twenty or more amino acids, and comprise the contiguous amino acids Ala-Lys-Pro-Arg (SEQ ID NO:l). The residues Ala- Lys-Pro-Arg are referred to herein as the tetramer.
  • the tetramer can be at any position in the peptide such that the peptide maintains yelosuppressive activity.
  • the additional residues in the peptide can be any amino acids so long as myelosuppressive activity is maintained.
  • the myelosuppressive activity of the peptides of the present invention can be determined as discussed hereinbelow.
  • the peptide comprises the sequence Lys-Ala-Lys-Pro-Arg (SEQ ID NO:2).
  • the peptide comprises the sequence Ala-Lys-Pro-Arg-Ala (SEQ ID NO:3).
  • the peptide comprises the sequence Glu-Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro (SEQ ID NO:4).
  • the biologically active peptide is Glu-Thr-Val-Ile-Met-Lys- Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro.
  • the peptide is Glu-Thr-Val-Ile-Met-Lys-Ala- Lys-Pro-Arg (SEQ ID NO:5).
  • the peptide is Ala-Lys-Pro-Arg-Ala-Asn-Phe- Pro (SEQ ID NO:6) 94/28013
  • the peptides of the present invention may be synthesized by methods known in the art.
  • the peptides may be derived by chemical or enzymatic cleavage from proteins or polypeptides containing the subject peptides.
  • the peptides are chemically synthesized by known methods including solution or solid phase synthetic procedures such as Merrifield synthesis, in which a protected amino acid is bound to a resin particle as an ester bond. Solid phase synthesis is commonly preferred for synthesis of longer peptides, and short peptides can be made efficiently by solution synthesis.
  • the peptides can be purified by art-recognized methods such as gel electrophoresis, silica gel or alumina chromatography, and high pressure liquid chromatography.
  • the myelosuppressive activity of the peptides of the present invention can be determined by standard assays which measure the proliferation of myeloid progenitor cells. Such assays are known to one of ordinary skill in the art.
  • the peptides of the present invention suppress the proliferation of a broad range of progenitor cell subsets, including mature subsets of granulo ⁇ yte-macrophage progenitor cells (CFU-GM) acrophage progenitors (CFU-M), and granulocyte progenitors (CFU-G), and early subsets of CFU-GM, erythroid (BFU-E) and multipotential (CFU-GEMM) progenitors.
  • CFU-GM granulo ⁇ yte-macrophage progenitor cells
  • CFU-M acrophage progenitors
  • CFU-G granulocyte progenitors
  • BFU-E erythroid
  • CFU-GEMM multipot
  • any one of a variety of known assays which measure the proliferation of such progenitor cells is appropriate for determining the suppressive activity of the present peptides.
  • the activity of the instant peptides is not species specific, and thus activity can be measured in assays using mammalian cells including, for example, human or mouse myeloid progenitor cells.
  • a typical assay measures granulocyte- acrophage colony and cluster formation and is described in U.S. Patent No. 5,149,544. Briefly, a single cell suspension of bone marrow cells from normal endotoxin resistant mice is prepared and cultured in soft agar medium. The concentration of cells per assay is typically 1 x 10 s cells/ml. Proliferation of CFU-GM is stimulated by the addition to each culture of murine GM- CSF. Each culture further contains a peptide of the present invention or control medium. Cultures are incubated in a fully humidified C0 2 environment, and total colonies (more than 50 cells) and clusters (4 to 50 cells) are scored after 5 to 8 days. The inhibitory activity of a peptide is measured as the amount that CSF-stimulated colony and cluster formation is decreased relative to assays with control medium.
  • Suitable variations of the above-described assay include measurement of suppression of colony formation of other subsets of mouse or human progenitor cells stimulated with appropriate growth factors or stimulants. Such variations include measurements of suppression of colony formation by immature subsets of ouse CFU-GM stimulated with recombinant murine GM-CSF alone or the combination of recombinant murine GM-CSF and recombinant murine Steel Factor (also known as mast cell growth factor and stem cell factor).
  • CFU-M mature macrophage progenitors
  • BFU-E immature erythroid
  • CFU-GEMM multipotential progenitors stimulated with recombinant human EPO
  • Other appropriate assays include, but are not limited to, measurement of suppression of colony formation by immature subsets of human CFU-GM stimulated with the combination of recombinant human GM-CSF and recombinant human Steel Factor, or mature CFU-GM stimulated with recombinant human GM-CSF, or mature granulocyte progenitor cells (CFU-G) stimulated with recombinant human G-CSF, or immature BFU-E stimulated with recombinant human EPO in combination with either recombinant human IL-3 or recombinant human Steel Factor, or immature CFU-GEMM stimulated with recombinant human EPO and recombinant human Steel Factor.
  • CFU-G mature granulocyte progenitor cells
  • the inhibitory activity of a peptide is measured as the amount that cytokine-stimulated colony and cluster formation is decreased, and can be expressed as the percent change in colony formation from control medium.
  • a peptide is considered to have suppressor activity if it is capable of significantly inhibiting colony formation (p ⁇ 0.05) relative to control medium in any of the above-described or similar assays.
  • the myelosuppressive activity of the peptides of the present invention can also be assessed by injecting the peptides into an experimental animal, such as a mouse, and determining effects on proliferation and absolute numbers of progenitor cells in femur and spleen, and on nucleated cellularity in bone marrow, spleen and blood.
  • an experimental animal such as a mouse
  • the effect of the peptides of the present invention on proliferation of myelopoietic progenitor cells can be determined as described by Maze et al. (1992) J. Immunol. 149:1004.
  • mice are injected intravenously (i.v.) with either sterile pyrogen-free saline or a peptide of the instant invention diluted in sterile pyrogen-free saline. Twenty-four hours after the single dose i.v. injection, mice are assessed for effects of the peptide on cycling rates (percentage of cells in the S-phase of the cell cycle) of femoral bone marrow and splenic CFU-GM, BFU-E and CFU-GEMM, and also on absolute numbers of progenitor cells and nucleated cells in bone marrow and spleen.
  • a peptide is considered to have suppressive effects of progenitor cell proliferation if the peptide is capable of significantly inhibiting absolute numbers of progenitors or percentage of progenitors in S-phase (p ⁇ 0.05) relative to saline controls in the above-described or a similar assay.
  • the present invention is further directed to the pharmaceutically acceptable salts of the instant peptides.
  • the salts include those prepared by standard methods with pharmaceutically acceptable inorganic acids such as hydrochloric, hydrobromic, nitric and sulfuric acids, and pharmaceutically acceptable organic acids such as citric, tartaric, fumaric, methanesulfonic and ethanesulfonic.
  • the preferred salt is hydrochloride. It has been found in accordance with the present invention that peptides comprising the sequence 94/28013
  • Ala-Lys-Pro-Arg are capable of inducing yelosuppression, i.e. suppressing the proliferation of myeloid progenitor cells, both in vitro and in vivo. Accordingly, the present peptides are useful in decreasing the proliferation of myeloid cells in hyperproliferative disease states in which the proliferative process has escaped regulation, such as leukemia and polycythemia vera.
  • a method of treatment of a myelopoietic hyperproliferative disorder responsive to a therapeutically effective amount of a peptide of the present invention which comprises administering a therapeutically effective amount of at least one peptide comprising the sequence Ala-Lys-Pro-Arg to a patient.
  • the peptide has the formula Ala-Lys-Pro-Arg.
  • the peptide has the formula Glu- Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro.
  • the peptide comprises the sequence Ala-Lys-Pro-Arg-Ala or Lys-Ala-Lys-Pro-Arg. In yet another embodiment the peptide comprises the sequence Glu-Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro. In another embodiment the peptide has the formula Glu- Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg. In yet another embodiment the peptide has the formula Ala-Lys-Pro-Arg- Ala-Asn-Phe-Pro. In accordance with the present invention, a therapeutically effective amount is defined as an amount which results in suppression of proliferation of myeloid progenitor cells. The effectiveness of treatment can be assessed by analysis of peripheral blood counts or of the freguency 94/28013
  • the hyperproliferative disorder is leukemia.
  • the leukemia is acute or chronic myelogenous leukemia.
  • the hyperproliferative disorder is polycythemia vera.
  • Chemotherapeutic agents and irradiation are known to cause severe myelosuppression due to their effects on rapidly proliferating cells. Chemotherapy- induced myelosuppression is the most common dose- limiting and potentially fatal complication of cancer treatment.
  • Hematopoietic growth factors including EPO, G-CSF and GM-CSF are currently used to stimulate hematopoiesis in patients with chemotherapy-induced myelosuppression.
  • Treatment of patients with the peptides of the present invention prior to chemotherapy or radiation and between courses of treatment can reversibly suppress the cycling rates of myeloid progenitors and thus reduce the population of cells subject to chemotherapy-induced damage. Treatment with the peptides of the present invention protects myeloid cells from the effects of chemotherapy and irradiation by placing the progenitors in a non-S phase portion of the cell cycle.
  • another aspect of the present invention provides a method of reducing chemotherapy- induced myelosuppression which comprises administering a therapeutically effective amount of at least one peptide comprising the sequence Ala-Lys-Pro-Arg to a patient prior to chemotherapy.
  • the peptide has the formula Ala- Lys-Pro-Arg.
  • the peptide has the formula Glu-Thr-Val-Ile-Met-Lys-Ala-Lys- Pro-Arg-Ala-Asn-Phe-Pro.
  • Peptides having the formulas Glu-Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg and Ala-Lys-Pro- Arg-Ala-Asn-Phe-Pro are also contemplated.
  • the peptide comprises the sequence Ala-Lys- Pro-Arg-Ala or Lys-Ala-Lys-Pro-Arg.
  • the peptide comprises the sequence Glu-Thr- al-Ile-Met-Lys-Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro.
  • a therapeutically effective amount is defined as an amount which results in suppression of proliferation of myeloid progenitor cells.
  • the effectiveness of treatment can be assessed by analysis of peripheral blood counts or of the frequency (colonies/cells plated) of hematopoietic progenitors (CFU-GEMM, BFU-E, CFU-GM) in bone marrow, or absolute number of such cells (colonies/ml of blood) in peripheral blood before and after treatment with the ⁇ subject peptides. Effects on proliferation can also be assessed by determining the percentage of progenitor cells in S-phase in bone marrow aspirates.
  • Endotoxin-induced septic shock is a disorder characterized by Gram negative bactere ia and sepsis accompanied by circulatory changes such as hypotension and disseminated intravascular coagulation resulting in multiple organ failure.
  • Septic shock is characterized by a cascade of physiological disturbances resulting in hypotension and resistance to vasoconstrictors.
  • Induction of nitric oxide synthase (NOS) in the vessel wall by endotoxin and cytokines mediates enhanced vasodilator tone and endothelial damage.
  • NOS nitric oxide synthase
  • Current therapeutics in development target specific events in the cascade and include anti-endotoxin products, nitric oxide inhibitors and cytokine inhibitors.
  • peptides comprising the sequence Ala-Lys-Pro-Arg are capable of reducing susceptibility to endotoxin-induced septic shock in a mammal at risk of septic shock.
  • the peptides contain from five to twenty amino acids and can be synthesized by art recognized methods, as discussed hereinabove.
  • the tetramer can be at any position in the peptide such that the peptide maintains the activity of reducing susceptibility to toxic shock.
  • the additional residues in the peptide can be any amino acids so long as biological activity (i.e. reduction of susceptibility to septic shock) is maintained.
  • the peptide comprises the sequence Ala-Lys-Pro-Arg-Ala.
  • the peptide comprises the sequence Lys-Ala- Lys-Pro-Arg.
  • the peptide comprises the sequence Glu-Thr-Val-Ile-Met-Lys-Ala-Lys- Pro-Arg-Ala-Asn-Phe-Pro.
  • the peptide has the formula Glu-Thr-Val-Ile-Met-Lys-Ala-Lys- Pro-Arg-Ala-Asn-Phe-Pro.
  • Peptides having the formulas Glu-Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg and Ala-Lys-Pro- Arg-Ala-Asn-Phe-Pro are also contemplated.
  • the efficacy of the peptides of the present invention in reducing susceptibility to septic shock can be assessed in an in vivo model which mimics a patient at risk of lethal endotoxin-induced septic shock.
  • an experimental animal such as a mouse is treated intravenously (i.v.) with a peptide of the present invention immediately prior to intraperitoneal (i.p.) injection of E. coli lipop ⁇ lysaccharide (LPS), the major toxic component of Gram negative bacterial endotoxin.
  • LPS E. coli lipop ⁇ lysaccharide
  • the dosage of LPS is 800 ⁇ g/mouse (40 g/kg) which is approximately 2LD 50 , and the majority of deaths occur between 24 and 48 hours after injection of LPS.
  • the preferred dosage of the peptide of the present invention is this model is about 10 ⁇ g.
  • Peptides which statistically significantly reduce mortality in this model relative to saline controls are considered to be effective in a method of prevention of septic shock in accordance with the present invention.
  • the present invention provides a method of prevention of endotoxin-induced septic shock which comprises administering a therapeutically effective amount of at least one peptide comprising the sequence Ala-Lys-Pro-Arg to a patient at risk of septic shock.
  • the peptide has the formula Ala-Lys-Pro-Arg.
  • the peptide has the formula Glu-Thr-Val-Ile-Met-Lys-Ala-Lys- Pro-Arg-Ala-Asn-Phe-Pro.
  • the peptide comprises the sequence Ala-Lys-Pro-Arg-Ala or Lys-Ala-Lys-Pro-Arg.
  • the peptide comprises the sequence Glu-Thr-Val-Ile-Met-Lys- Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro.
  • Peptides having the formulas Glu-Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg and Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro are also contemplated.
  • endotoxin and cytokines cause induction of nitric oxide (NO) synthase in the endothelium and vascular smooth muscle and in other cells and tissues.
  • NO nitric oxide
  • Enhanced NO synthesis has a cytotoxic effect characterized by increased vasodilation, endothelial damage and damage to other cells (see, for example. Palmer (1993) Arch. Surg. 128:396) , and is thus contributory to cardiovascular collapse associated with the lethal phase of septic shock.
  • the peptides of the present invention are capable of reducing susceptibility to endotoxin-induced septic shock.
  • the peptides of the invention interfere with the action of LPS
  • the major toxic component of bacterial endotoxin LPS is known to be a potent stimulant of inducible nitric acid synthase (NOS), the enzyme which catalyzes the synthesis of NO.
  • NOS inducible nitric acid synthase
  • the peptides of the present invention reduce NO-induced pathological effects of cytotoxic shock, i.e. NO-induced hypotension.
  • the present peptides may be administered to a host as a pharmaceutical composition in a therapeutically effective amount.
  • the pharmaceutical compositions contain a therapeutically effective dosage of the peptides according to the present invention together with a pharmaceutically acceptable carrier.
  • the skilled artisan can determine the dosage of the present therapeutic peptides and compositions which will be most suitable and it will vary with the form of administration and the particular peptide chosen, and furthermore, it will vary with the particular patient under treatment. Generally treatment is initiated with small dosages, substantially less than the optimum dose of the compound, and the dosage is increased by small increments until the optimum effect under the circumstances is reached. It will generally be found that when the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally.
  • the peptides are useful in the same manner as comparable therapeutic agents and the dosage level is of the same order of magnitude as is generally employed with those other therapeutic agents.
  • the therapeutic doses of the peptides of the present invention are generally effective, even in the nanomolar range, and these compounds are effective in micromolar quantities in the range of from about 10 to about 500 mg/kg of body weight of treated mammal.
  • the compounds are administered generally in dosage of, for example 0.01 mg/kg to about 200 mg/kg, also depending upon the host and effect desired.
  • the preferred dosage ranges from 0.5 to 10 mg/kg of body weight of treated mammal.
  • the compositions can be administered by well- known routes including oral, intravenous (if soluble), intramuscular, intranasal, intradermal, subcutaneous, parenteral, enteral and the like. Depending on the route of administration, the pharmaceutical composition may require protective coatings.
  • the pharmaceutical forms suitable for injectionable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the ultimate solution form must be sterile and fluid.
  • Typical carriers include a solvent or dispersion medium containing, for example, water buffered aqueous solutions (i.e., bio ⁇ ompatible buffers), ethanol, polyol such as glycerol, propylene glycol, polyethylene glycol, suitable mixtures thereof, surfactants or vegetable oils.
  • Sterilization can be accomplished by an art-recognized technique, including but not limited to, addition of antibacterial or antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic acid or thimer ⁇ sal. Further, isotonic agents such as sugars or sodium chloride may be incorporated in the subject compositions.
  • antibacterial or antifungal agents for example, paraben, chlorobutanol, phenol, sorbic acid or thimer ⁇ sal.
  • isotonic agents such as sugars or sodium chloride may be incorporated in the subject compositions.
  • sterile injectable solutions containing the subject peptides is accomplished by incorporating these peptides in the required amount in the appropriate solvent with various ingredients enumerated above, as required, followed by sterilization, preferably filter sterilization. To obtain a sterile powder, the above solutions are vacuum- dried or freeze-dried as necessary.
  • the pharmaceutical compositions thereof containing an effective dosage of the peptide may also contain an inert diluent, an assimilable edible carrier and the like, be in hard or soft shell gelatin capsules, be compressed into tablets, or may be in an elixir, suspension, syrup or the like.
  • the 14-mer peptide Glu-Thr-Val-Ile-Met-Lys- Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro was synthesized by solid phase synthesis at the peptide facility of the Department of Medicine, Veterans Administration Medical Center, University of Tennessee, Memphis, TN.
  • the peptide was purified by G-10 Sephadex chromatography, and the amino acid analysis performed by the Molecular 0 Biology Resource Facility, University of Tennessee, Knoxville was compatible with the molar ratios of the peptide. This was confirmed at Indiana University School of Medicine.
  • Antibodies to 14-mer peptide and rat liver 5 . . ferritin were raised in female New Zealand white rabbits purchased from Myrtles Rabbitry, Thompson Station, TN.
  • IgG was prepared by affinity purification over immobilized 14-mer peptide. Seven mg of peptide with free amine groups blocked with citraconic anhydride were coupled to 2 ml of diaminodipropylamine gel using 1-
  • the proteins were transferred to Immobilon-P PVDF membranes using a c BioTrans se idry electrophoretic transfer unit with 0.025 M Tris-buffer, pH 8.5, containing 0.19 M glycine and 0.1 M SDS. Following washing in Tris-buffered saline (TBS), pH 7.5, for 15 min., the membranes were blocked with 3% nonfat dry milk in TBS for 30 min. at _ 0 37°C and washed again with TBS containing 0.05 Tween 20 (TBS-Tween). The membranes were incubated overnight at room temperature with the appropriate antibody in TBS-
  • TBS Tris-buffered saline
  • I munoglobulin G antibodies were prepared from sera of rabbits immunized with ferritin and the 14-mer
  • the anti-peptide IgG was further purified by affinity purification using immobilized peptide.
  • the antibodies showed minimal cross-reactivity between ferritin and the 14-mer peptide when assessed by ELISA, thus demonstrating the lack of im uno-relatedness of the 14-mer and ferritin.
  • soluble ferritin did not reduce the binding of anti-peptide to peptide affixed in ELISA wells although soluble peptide effectively competed for the antibodies.
  • Similar results were obtained when ferritin and the 14-mer o peptide were used as competitors in a ferritin/anti- ferritin ELISA, i.e., the peptide did not compete while ferritin significantly reduced antibody binding to affixed antigen.
  • anti-peptide at 600 ng/ l final concentration was added
  • This example demonstrates the suppressive effect of the 14-mer peptide against proliferation of murine CFU-GM.
  • CFU-GM bone marrow granulocyte-macrophage progenitor cells
  • CFU-GM Granulocyte-Macrophage Progenitor Cells
  • Results are expressed as mean + 1 SEM for 3 plates/point. to Significant % change from control medium, p ⁇ 0.001 based on a two-tailed student's t-test; other values not significantly different from control, p > 0.05.
  • the 14-mer peptide (NH 2 -ETVIMKAKPRANFP-COOH) has a broad range of activities on different subsets of myeloid progenitor cells, and this activity is apparent on both murine (Table 2) and human (Table 3) progenitors.
  • the 14-mer peptide suppressed proliferation of murine bone marrow immature CFU-GM stimulated with rmuGM-CSF, mature macrophage progenitors (CFU-M) stimulated with muCSF-1 and immature erythroid (BFU-E) and multipotential (CFU-GEMM) progenitors stimulated with 1 U/ml rhu erythropoietin (Amgen).
  • M ⁇ P-lO ⁇ rmu macrophage inflammatory protein (M ⁇ P)-lO ⁇ (R & D Systems) that has suppressive activity against immature CFU-GM, BFU-E and CFU-GEMM (Broxmeyer et al. Blood 76:1110, 1990; J. Immunol. 147:2586, 1991; Mantel et al. Proc. Natl. Acad. Sci. USA 90:2232, 1993), did not have activity on the mature CFU- M, thus distinguishing the 14-mer peptide from MlP-lO ⁇ (Table 2).
  • the 14-mer peptide had suppressive activity on human bone marrow immature CFU- GM stimulated with rhuGM-CSF (Immunex Corporation) plus rhuSLF (Immunex Corporation) mature CFU-GM stimulated by rhuGM-CSF, mature granulocyte progenitor cells (CFU-G) stimulated by rhu granulocyte colony stimulating factor (G-CSF; Immunex Corporation), immature BFU-E stimulated with rhuEpo plus either rhu interleukin (IL)-3 (Immunex Corporation) or rhuSLF and immature CFU-GEMM stimulated by rhuEpo plus rhuSLF.
  • IL interleukin
  • Results are based on the mean _+ 1 SEM of 3 plates/point.
  • mice were injected i.v. with 0.2 ml of sterile pyrogen-free saline, or 0.2 ml (containing 2 ng) of the 14-mer peptide or a scrambled 14-mer peptide. Mice were sacrificed 24 hours later. These studies were done exactly as reported for the in vivo action of rmuMIP-l ⁇ (Maze et al. J. Immunol. 149:1004, 1992). Results shown are the means + 1 SEM for one representative experiment in which a total of 4 mice per group were each individually assessed.
  • the sequence of the 14-mer peptide is: NH 2 -Glu-Thr-Val-Ile-Met-Lys-Ala-Lys-Pr ⁇ - Arg-Ala-Asn-Phe-Pro-COOH.
  • the sequence of the scrambled 14-mer peptide is: NH 2 -Glu-Ala-Thr-Lys-Val-Pro-Ile-Arg- Met-Lys-Phe-Ala-Asn-Pro-COOH (SEQ ID NO:7).
  • the in vivo activity of the 14-mer peptide is demonstrated by the results in Table 5, which shows that 24 hours after an iv injection of 2 ng 14-mer peptide, there is a significant decrease in the absolute numbers of femoral marrow and splenic granulocyte-macrophage (CFU-GM), erythroid (BFU-E) and multipotential (CFU- GEMM) progenitor cells, and in the cycling rates (percentage of progenitors in S-phase of the cell cycle) of these cells.
  • CFU-GM femoral marrow and splenic granulocyte-macrophage
  • BFU-E erythroid
  • CFU- GEMM multipotential progenitor cells
  • the specificity of the 14-mer peptide is demonstrated by the inability of the scrambled 14-mer peptide (also inactive in vitro; see Table 1) to suppress myeloid progenitor cells in vivo (Table 5).
  • mice Five week old female Balb/c mice were injected i.v. with a single dose of the 14-mer peptide Glu-Thr- Val-Ile-Met-Lys-Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro at a 5 dose ranging from 1 ⁇ g - 1.0 mg/mouse in 0.1 ml of PBS pH 7.0 immediately prior to i.p. injection of 800 ⁇ g E. coli LPS (phenol-water extraction, Sigma). The influence of the peptide on survival is shown in Table 6. Lethality represents deaths occurring within 72 ° hours. The efficacious dose (10 ⁇ g) saved 50% of mice given LPS sufficient to kill 80 - 100% of controls.
  • mice Five week old female Balb/c mice were injected i.v. with a single 10 ⁇ g dose of the 14-mer peptide or carrier buffer immediately prior to i.p. injection of 100-800 ⁇ g E. coli LPS.
  • the influence of the peptide on survival is shown in Table 7. Lethality represents deaths occurring within 72 hours.
  • the 14-mer peptide enhances resistance to lethal endotoxin shock.
  • the inhibitory influence of the 14-mer peptide (Glu-Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg-Ala-Asn-Phe- Pro), a 10-mer peptide (Glu-Thr-Val-Ile-Met-Lys-Ala-Lys- Pro-Arg) and an 8-mer peptide (Ala-Lys-Pro-Arg-Ala-Asn- Phe-Pro) on colony formation by murine marrow progenitors was examined.
  • sodium nitroprusside (SNP) a generator of NO in aqueous solution
  • SNP sodium nitroprusside
  • Table 8 sodium nitroprusside (SNP)
  • the peptides of the present invention inhibit stimulation of colony formation by transitional progenitors stimulated by either LPS or SNP, indicating that NO produced in response to LPS is responsible for stimulation of S- phase positive transitional progenitors and that the peptides interfere with the effects of NO. /28013
  • MOLECULE TYPE peptide x
  • SEQUENCE DESCRIPTION SEQ ID NO:3:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des peptides contenant la séquence Ala-Lys-Pro-Arg présentent des effets suppresseurs sur la prolifération d'un large éventail de cellules souches myélopoïétiques. Dans un mode de réalisation préféré, le peptide présente la séquence Glu-Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro. Les peptides de l'invention sont utiles dans le traitement de troubles hyperprolifératifs myélopoïétiques, et dans la production de cellules myéloïdes contre une détérioration induite par chimiothérapie et par rayonnement. Des peptides contenant la séquence Ala-Lys-Pro-Arg sont également utiles dans le traitement du choc septique induit par endotoxine.
EP94916812A 1993-05-20 1994-05-18 Peptides de suppression de la proliferation de cellules souches myeloides et de traitement du choc septique Withdrawn EP0698039A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6572293A 1993-05-20 1993-05-20
US65722 1993-05-20
PCT/US1994/005773 WO1994028013A1 (fr) 1993-05-20 1994-05-18 Peptides de suppression de la proliferation de cellules souches myeloides et de traitement du choc septique

Publications (1)

Publication Number Publication Date
EP0698039A1 true EP0698039A1 (fr) 1996-02-28

Family

ID=22064655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94916812A Withdrawn EP0698039A1 (fr) 1993-05-20 1994-05-18 Peptides de suppression de la proliferation de cellules souches myeloides et de traitement du choc septique

Country Status (4)

Country Link
EP (1) EP0698039A1 (fr)
JP (1) JPH08510745A (fr)
CA (1) CA2162610A1 (fr)
WO (1) WO1994028013A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0952828B1 (fr) 1996-11-13 2006-08-16 Cold Spring Harbor Laboratory Utilisations therapeutiques d'inhibiteurs d'oxyde nitrique
US6593372B2 (en) 1996-11-13 2003-07-15 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
FR2903311B1 (fr) * 2006-07-10 2012-06-15 Centre Nat Rech Scient Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
CN113952446B (zh) * 2021-09-03 2023-12-05 河南省医药科学研究院 生物活性肽在抑制骨髓毒性中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA838780B (en) * 1982-11-26 1985-01-30 Nyegaard & Co As Peptide compounds
IL77323A0 (en) * 1985-12-13 1987-01-30 Yeda Res & Dev Immunizing preparation comprising tuftsin or an analog thereof
US5149544A (en) * 1989-11-13 1992-09-22 Research Corporation Technologies, Inc. Method of inhibiting progenitor cell proliferation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9428013A1 *

Also Published As

Publication number Publication date
JPH08510745A (ja) 1996-11-12
CA2162610A1 (fr) 1994-12-08
WO1994028013A1 (fr) 1994-12-08

Similar Documents

Publication Publication Date Title
Leizer et al. Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor
AU621582B2 (en) Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
US5359032A (en) Interkeukin-1 inhibitor
US6204364B1 (en) Hybrid cytokines
Graham et al. Aggregation of the chemokine MIP-1 alpha is a dynamic and reversible phenomenon. Biochemical and biological analyses.
EP0326120B1 (fr) IFN-bêta2/IL-6 humain, sa purification et ses utilisations
AU590543B2 (en) Purification of native colony stimulating factor-1
US5475087A (en) Antagonists of human granulocyte-macrophage colony stimulating factor derived from the carboxyl terminus
WO1992002240A2 (fr) Compositions et procedes nouveaux pour le traitement des maladies angiogeniques
US5792450A (en) Purified human CSF-1
US6355619B1 (en) Peptide tumor cell growth inhibitors
US5869055A (en) Anti-inflammatory CD14 polypeptides
WO1991008231A1 (fr) FACTEUR POLYPEPTIDIQUE [Ala IL-8]77 UTILISE COMME INIHIBITEUR D'ADHESION DES LEUCOCYTES
US5543143A (en) Method for activating macrophages/monocytes
EP0698039A1 (fr) Peptides de suppression de la proliferation de cellules souches myeloides et de traitement du choc septique
EP0341273B1 (fr) Substances biologiques et procedes de production et d'utilisation de ces substances biologiques en therapeutique
CA2040969C (fr) Utilisation du facteur de croissance transformant de type beta pour accroitre le nombre de macrophages et de granulocytes
AU691085B2 (en) Anti-inflammatory CD14 polypeptides
US5942220A (en) Inhibitor of cytokine activity and applications thereof
JPH04506818A (ja) 造血細胞の成熟
US5693481A (en) Inhibitor of cytokine activity and applications thereof
US5650147A (en) Methods of stimulating granulocyte-macrophage progenitor cells
AU638473B2 (en) Promoters of colony stimulating factor activity
US6403553B1 (en) Use of polypeptides for treating thrombocytopenia
JPH09510688A (ja) Ｃｘｃインタークリン分子のペプチド阻害剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI NL SE

17Q First examination report despatched

Effective date: 19960307

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960718